STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3702 by analyst upside · 2026-06-27
APGE
Apogee Therapeutics, Inc.
Healthcare · Market Cap $10B · P/E 0x
ANALYST PRICE TARGET
-1.5%
implied upside to consensus target
Current Price $132.55
Consensus Target $130.53
Bull Target $137.0
Bear Target $81.0
Analysts Covering 12
ANALYST CONSENSUS — BUY
Strong Buy
0
Buy
10
Hold
2
Sell
0
52-Week Low $34.34
52-Week High $133.16
YTD Return +74.9%
FUNDAMENTALS
Market Cap $10B
P/E Ratio (TTM) N/A
Forward P/E -25.5x
EPS (TTM) $-4.33
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $34.34
52-Week High $133.16
Current Price $132.55
Bear Target $81.0
Bull Target $137.0
● Now $132.55 ● Target $130.53
TRADING DATA
Avg Volume 2.2M
YTD Return +74.9%
Analyst Count 12
Consensus Buy
Upside to Target -1.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Apogee Therapeutics, Inc. (APGE) is currently trading at $132.55 with a Wall Street consensus price target of $130.53, which is 1.5% below the current price over the next 12 months. 12 analysts currently cover APGE, with a consensus rating of Buy — 83% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $137.0, while the most cautious has a target of $81.0.

APGE operates in the Healthcare sector with a market capitalisation of $10B. The stock is up 74.9% year-to-date and is currently trading near the upper end of its 52-week range of $34.34 – $133.16.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for APGE, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-06-08 Building track record
Truist Securities — Reiterated
Hold → Hold 2026-05-27 Building track record
BTIG reit
Buy → Buy 2026-05-27 38% win rate (8 calls)
Wedbush — Reiterated
Outperform → Outperform 2026-05-27 Building track record
Rothschild & Co ● Initiated
Buy 2026-05-01 Building track record
Mizuho — Reiterated
Outperform → Outperform 2026-03-30 Building track record
Citigroup — Reiterated
Buy → Buy 2026-03-24 Building track record
Canaccord Genuity — Reiterated
Buy → Buy 2026-03-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →